Business
PharmaDrug Collaborates with PharmaTher for Development of DMT Transdermal Patch
PharmaDrug is positioning to become a leader of DMT-based therapeutics for ocular disease and neu...
About this update from Pharmadrug, Inc.
[{"type":"text","content":"PharmaDrug Collaborates with PharmaTher for Development of DMT Transdermal PatchPharmaDrug is positioning to become a leader of DMT-based therapeutics for ocular disease and neuropsychiatric conditionsToronto, Ontario--(Newsfile Corp. - February 22, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (\"PharmaDrug\" or the \"Company\"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. (\"PharmaTher\") to evaluate the delivery of N,N-Dimethyltryptamine (DMT) using PharmaTher's novel microneedle patch (MN-Patch) delivery technology. Daniel Cohen, CEO and Chairman of PharmaDrug, commented, \"We are excited to commence a collaboration with PharmaTher, a leader in microneedle patch delivery of psychedelics. We believe our combined programs and expertise in drug delivery and pharmacology, specifically relating to DMT, set the stage for the potential development of new treatment options for mental health conditions.\"PharmaTher has completed a non-clinical research study with Terasaki Institute for Biomedical Innovation (TIBI) evaluating the delivery of its DMT MN-Patch. Research results from this study will be available in early Q2-2023 and will be used to support a potential human clinical study. Based on the results, PharmaDrug and PharmaTher will finalize a product and clinical development plan to initiate regulatory discussions for future clinical studies in various indications where DMT may have promise such as major depressive disorder. PharmaTher recently entered into a researcher collaboration agreement with its MN-Patch technology with Revive Therapeutics Ltd. to evaluate the delivery of 3,4-Methylenedioxy​methamphetamine (MDMA).In addition to developing cepharanthine for cancer and infectious diseases, PharmaDrug continues to build a specialty psychedelics program focusing on novel uses and delivery forms of DMT and other undisclosed psychedelic tryptamines as a potential treatment for ocular disease and neuropsychiatric conditions. The Company's DMT programs include: discovery of novel DMT-analogue and delivery device in partnership with TIBI for the treatment of primary open angle glaucoma;advancement o...